Insmed rises as late‑stage trial backs wider use of lung disease drug

Shares of drugmaker Insmed INSM.O rise 9.4% to $148.79 premarket

Co says inhaled antibiotic Arikayce helped patients with MAC lung disease, a rare lung infection that causes long‑lasting cough, fatigue and breathing problems

Says late‑stage study tested Arikayce with standard drugs in newly diagnosed patients

Nearly 88% of patients cleared the infection by month six vs 57% on placebo; benefit lasted through month 15, co says

Says main goal of the study is to help patients clear the lung infection and improve breathing symptoms

Side effects such as cough and voice changes were more common; serious side effects seen in 14% vs 11% on placebo - INSM

Co says it plans to seek U.S. and Japan approval to expand use of Arikayce later this year

Shares rose about twofold in 2025